We compared serum levels of complement components (C3, C4, C1q), activation products (C3a, C4a, C5a, Ba, Bb, sC5b-9), and regulators (Factor I, Factor H) between patients who developed irMyositis or irNeuropathy, ICI-treated cancer patients without irAEs, and healthy controls. This evidence concerns the gene C4A and cancer.